Skip to main content
Psychedex
Article

Zolpidem Facts

Depressant; Hypnotic; Sedative; Imidazopyridine; GABA-A receptor positive allosteric modulator

Description

Zolpidem — sold as Ambien and Stilnox — is a sedative-hypnotic of the imidazopyridine class. It boosts the brain's primary calming signal, GABA, with a strong preference for the receptors that govern sleep onset, producing rapid sedation.[1]

Subjective effects include rapid sedation, sleep facilitation, anterograde amnesia, and at higher doses visual hallucinations and euphoria. At prescribed doses the experience is unremarkable drowsiness descending into sleep; at higher amounts a dreamlike, hallucinatory state emerges, defined by an inability to recognize one's own impairment.[2]

Dependence develops with chronic high-dose use, and abrupt withdrawal at extreme doses risks seizures;[3] single-agent overdose is rarely fatal and reversible.[4] The defining danger is impairment users cannot detect — cognitive deficits persist through the night for weeks,[5] and sleep behaviors can endanger others.

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight5 – 10 mgCommon10 – 20 mgStrong20 – 40 mgHeavy40+ mg

Starts in 15 – 30 minLasts 4 – 7 hoursAfter-effects 2 – 6 hours

Body and dependence

Acute toxicity
Low
Chronic toxicity
Moderate
Physical dependence
Moderate
Psychological dependence
Moderate
Withdrawal
Severe · medical supervision
Compulsive redosing
Moderate

Tolerance

Builds
Slow
Fully resets after
Not recorded
Carries over to
benzodiazepines; zopiclone; zaleplon; alcohol

Effectslikely at a common dose

Perception
none likely · 6 possible, including Visual acuity suppression, Vestibular distortion, Visual haze / noise
Body
Sedation; Physical fatigue; +4 possible, including Motor control impairment, Dizziness
Thinking
Cognitive impairment; +13 possible, including Analysis suppression, Decision impairment, Information processing suppression
Feeling
none likely · 2 possible
Self
none likely · 1 possible
Time
none likely · 2 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Prior complex sleep behaviors on zolpidem; Severe hepatic impairment; Pediatric use; Known hypersensitivity to zolpidem
Relative
Severe respiratory insufficiency; Obstructive sleep apnea; Myasthenia gravis; Active substance use disorder; Pregnancy; Breastfeeding; Elderly

Combinations60 recorded

Lethal (1)
Opioids
Dangerous (21)
Alpha-2 adrenergic receptor antagonist; Antipsychotics; Atypical antipsychotics; Benzodiazepines; Buprenorphine, Kratom; Cannabis, THC; Clonidine, Guanfacine; Gabapentin, Pregabalin; GHB, Baclofen; GHB, GBL; Local anesthetics; Naltrexone; SNRIs; Stimulants; Synthetic cannabinoids; Ibogaine; Ketamine, DXM, PCP; MAOIs; NSAIDs; Poppers (Alkyl nitrites); Poppers, Nitrates
Caution (26)
See full page: psychedex.org/substances/zolpidem
Not graded (12)
Not listed never means safe.

Seek help immediately if

  • Extreme drowsiness — can't stay awake or be roused
  • Confusion, slurred speech, severe loss of coordination
  • Slow, shallow, or irregular breathing
  • Unconsciousness / unresponsive; limp, floppy body
  • Blue lips or fingertips
  • Vomiting while sedated (choking / aspiration risk)
  • Cold, clammy skin; weak pulse

What to do

  1. Try to wake them — shout, firm sternal rub
  2. If unresponsive or breathing is impaired, call emergency services
  3. Place them in the recovery position — critical, they can choke on vomit
  4. Monitor breathing continuously; be ready to give rescue breaths / CPR
  5. Never leave them alone to "sleep it off"
  6. Do not give other drugs, stimulants, or more depressants

Most depressant overdoses resolve with airway protection, breathing support, and monitoring. The danger is respiratory depression and choking on vomit — sharply worse when combined with opioids or alcohol. GHB/GBL overdoses often involve sudden deep unconsciousness and may self-resolve, but airway protection is essential.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Soderhielm PC, Balle T, Bak-Nyhus S, Zhang M, Hansen KM, Ahring PK, Jensen AA (2018) Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors — Biochemical Pharmacology doi:10.1016/j.bcp.2018.08.019
  2. [2]
    ^Schoedel KA, Sun H, Sellers EM, et al. (2016) Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study — Journal of Clinical Psychopharmacology doi:10.1097/jcp.0000000000000516
  3. [3]
    ^Wang LJ, Ree SC, Chu CL, Juang YY (2011) Zolpidem dependence and withdrawal seizure--report of two cases — Psychiatria Danubina PMID:21448102
  4. [4]
    ^Lheureux P, Debailleul G, De Witte O, Askenasi R (1990) Zolpidem intoxication mimicking narcotic overdose: response to flumazenil — Human & Experimental Toxicology PMID:2111156
  5. [5]
    ^Kleykamp BA, Griffiths RR, McCann UD, Smith MT, Mintzer MZ (2012) Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use — Experimental and Clinical Psychopharmacology doi:10.1037/a0025237
Print version
Report an issue